Sort   by:  
 Page size 
ProteomicsOuter membrane vesicles catabolize lignin-derived aromatic compounds in Pseudomonas putida KT2440
Lignin modifications and the exoproteome of three aromatic catabolic bacteria: Pseudomonas putida KT2440, Rhodoccocus jostii RHA1, and Amycolatopsis sp. ATCC 39116. Samples were digested with trypsin, then analyzed by LC-MS/MS. Data was searched with MSGF+ and abundances inferred using PNNL's DMS an...
ORGANISM(S): Pseudomonas Putida Kt2440 (ncbitaxon:160488) Amycolatopsis Sp. Atcc 39116 (ncbitaxon:385957) Rhodococcus Jostii Rha1 (ncbitaxon:101510) 
2019-11-01 | MSV000084524 | MassIVE
ProteomicsPathogenic Natural Antibodies Recognizing Annexin IV Are Required to Develop Intestinal Ischemia-Reperfusion Injury
Intestinal ischemia-reperfusion (IR) injury is initiated when natural IgM antibodies recognize neo-epitopes that are revealed on ischemic cells. The target molecules and mechanisms whereby these neo-epitopes become accessible to recognition are not well understood. Proposing that isolated intestinal...
ORGANISM(S): Mus musculus 
2010-05-05 | E-GEOD-14862 | biostudies-arrayexpress
Genomicsena-DATASET-GNE-27-07-2018-23:28:18:139-1120 - samples
Tumor DNA was extracted from formalin-fixed and paraffin embedded tumors of a large cohort of bladder cancer patients before treatment with anti-PD-L1. Normal DNA was extracted from matched PBMCs. Whole exome sequencing was performed. This is a subset of patients for which RNA sequencing is also pro...
EGAD00001004218 | EGA
Genomicsena-DATASET-GNE-22-02-2018-22:43:32:906-1098 - samples
RNA was extracted from formalin-fixed and paraffin embedded tumors of a large cohort of bladder cancer patients before treatment with anti-PD-L1. RNA was sequenced using a capture based approach (exome capture, RNA access).
EGAD00001003977 | EGA
GenomicsTGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
We examined tumours from a large cohort of patients with metastatic urothelial bladder cancer (mUC) treated with an anti–PD-L1 agent (atezolizumab) and identified major determinants of clinical response and immune escape. Whole transcriptome profiles were generated for 368 patients using TruSeq RNA ...
EGAS00001002556 | EGA
GenomicsData access committee handling data access requests for biomarker data from the clinical trial IMvigor210.
Data Access Committee EGAC00001000945
EGAC00001000945 | EGA
GenomicsEGAD00000000114
Whole transcriptome sequence data from 18 ovarian clear-cell carcinoma samples and one TOV21G ovarian clear-cell carcinoma cell line
EGAD00000000114 | EGA
GenomicsARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
We have sequenced the whole transcriptomes of 18 ovarian clear-cell carcinomas and 1 ovarian clear-cell carcinoma cell line and found somatic mutations in ARID1A (the AT-rich interactive domain 1A [SWI-like] gene) in 6 of the samples. ARID1A encodes BAF250a, a key component of the SWI–SNF chromati...
EGAS00000000075 | EGA
GenomicsWhole genome sequencing - samples
Mutational landscapes of primary triple negative breast cancers - WGS
EGAD00001000115 | EGA
GenomicsRNA seq - samples
Mutational landscapes of primary triple negative breast cancers - RNA seq
EGAD00001000132 | EGA
Sort   by:  
 Page size